[go: up one dir, main page]

MX2018005411A - Polipeptidos anti il-23. - Google Patents

Polipeptidos anti il-23.

Info

Publication number
MX2018005411A
MX2018005411A MX2018005411A MX2018005411A MX2018005411A MX 2018005411 A MX2018005411 A MX 2018005411A MX 2018005411 A MX2018005411 A MX 2018005411A MX 2018005411 A MX2018005411 A MX 2018005411A MX 2018005411 A MX2018005411 A MX 2018005411A
Authority
MX
Mexico
Prior art keywords
amino acid
acid sequences
linkers
seq
relates
Prior art date
Application number
MX2018005411A
Other languages
English (en)
Inventor
Buyse Marie-Ange
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2018005411A publication Critical patent/MX2018005411A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a secuencias de aminoácidos que están dirigidas en contra de IL-23. Las secuencias de aminoácidos de la presente invención comprenden dos nanoanticuerpos anti IL-23 y un nanocuerpo anti albúmina de suero, unidos por dos conectores (conectores 9GS). En particular, la invención se refiere a las secuencias de aminoácidos de SEQ ID NO: 2 y SEQ ID NO: 3 (enumeradas en la Tabla 1 y la Figura 1).
MX2018005411A 2015-10-30 2016-10-28 Polipeptidos anti il-23. MX2018005411A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562248468P 2015-10-30 2015-10-30
PCT/EP2016/076076 WO2017072299A1 (en) 2015-10-30 2016-10-28 Polypeptides against il-23

Publications (1)

Publication Number Publication Date
MX2018005411A true MX2018005411A (es) 2018-08-15

Family

ID=57218890

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005411A MX2018005411A (es) 2015-10-30 2016-10-28 Polipeptidos anti il-23.

Country Status (13)

Country Link
US (2) US10968271B2 (es)
EP (1) EP3368569B1 (es)
JP (1) JP6936797B2 (es)
KR (1) KR20180072819A (es)
CN (1) CN108350069B (es)
AU (1) AU2016347610A1 (es)
BR (1) BR112018008754A2 (es)
CA (1) CA3003539A1 (es)
IL (1) IL258897A (es)
MX (1) MX2018005411A (es)
RU (1) RU2018119732A (es)
SG (1) SG11201803416VA (es)
WO (1) WO2017072299A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810124PA (en) * 2014-05-16 2018-12-28 Ablynx Nv Improved immunoglobulin variable domains
KR20250099289A (ko) * 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
EP3368569B1 (en) 2015-10-30 2021-02-24 Ablynx NV Polypeptides against il-23
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
CN114920839B (zh) * 2022-06-17 2023-03-10 天津大学 特异性结合il-23的纳米抗体及其用途
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
CN120712282A (zh) 2023-02-17 2025-09-26 阿布林克斯有限公司 结合新生儿fc受体的多肽

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
CA2706200A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
US9464138B2 (en) 2009-04-30 2016-10-11 Ablynx N.V. Method for the production of domain antibodies
WO2010142534A1 (en) * 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
MX2012005345A (es) 2009-12-23 2012-06-08 Esbatech Alcon Biomed Res Unit Metodo para disminuir inmunogenicidad.
EP2563814A1 (en) 2010-04-30 2013-03-06 Ablynx N.V. Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
EP2596022A4 (en) * 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
DE102011077786A1 (de) 2011-06-20 2012-12-20 Continental Teves Ag & Co. Ohg Aktuatorsystem und Betriebsverfahren für ein Aktuatorsystem
PL2723769T5 (pl) 2011-06-23 2022-10-17 Ablynx Nv Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
EP3368569B1 (en) 2015-10-30 2021-02-24 Ablynx NV Polypeptides against il-23
CA3005488A1 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders

Also Published As

Publication number Publication date
AU2016347610A1 (en) 2018-05-10
CN108350069B (zh) 2021-11-12
BR112018008754A2 (pt) 2018-10-30
US20210188967A1 (en) 2021-06-24
WO2017072299A1 (en) 2017-05-04
JP2018538251A (ja) 2018-12-27
KR20180072819A (ko) 2018-06-29
EP3368569A1 (en) 2018-09-05
IL258897A (en) 2018-06-28
US11753465B2 (en) 2023-09-12
EP3368569B1 (en) 2021-02-24
CN108350069A (zh) 2018-07-31
RU2018119732A3 (es) 2020-03-24
CA3003539A1 (en) 2017-05-04
SG11201803416VA (en) 2018-05-30
US20180312583A1 (en) 2018-11-01
US10968271B2 (en) 2021-04-06
RU2018119732A (ru) 2019-12-03
JP6936797B2 (ja) 2021-09-22

Similar Documents

Publication Publication Date Title
MX2018005411A (es) Polipeptidos anti il-23.
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
MX2017006866A (es) Pares de unión para producción de péptidos.
PH12018501355A1 (en) Rsv f protein mutants
PH12019500596B1 (en) Recombinant binding proteins and their use
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
MX382929B (es) Polipéptido heterodimerizado.
WO2014202616A3 (en) Rasamsonia gene and use thereof
SG10201909716RA (en) Modified j-chain
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014CN00414A (es)
NZ628625A (en) Polypeptides binding to human complement c5
EA201690651A1 (ru) Содержащие cmp высокобелковые композиции денатурированного сывороточного белка, содержащие их продукты и их применения
MX384984B (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
WO2014136064A3 (en) Immunogenic fusion polypeptides
MX2024005946A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
EP4374913A3 (en) Novel human serum albumin mutant
MY176200A (en) Binding polypeptides having a mutated scaffold
MX2021001129A (es) Metodo de purificacion de antigenos.
WO2015107363A3 (en) Mycobacterial antigen composition
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins